Drug Profile


Alternative Names: TAK-438; TAKECAB; VONOPION® pack; Vonoprazan fumarate; VONOSAP® pack 400; VONOSAP® pack 800

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Amines; Antiulcers; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 05 Nov 2016 Takeda initiates a phase III trial for non-erosive Gastro-oesophageal reflux in Japan (PO, Tablet) (JapicCTI163413; NCT02954848)
  • 02 Sep 2016 Takeda plans a phase I drug-interaction trial for Helicobacter infections (Combination therapy) in South Korea (PO, Tablet) (NCT02892409)
  • 01 Sep 2016 Phase-I clinical trials in Helicobacter infections (Combination therapy) in South Korea (PO) (NCT02892409)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top